Skip to main content

BPMC

Stock

BPMC

Stock
Health Care
Biotechnology

Performance overview

BPMC Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
48.21%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Company info

SectorHealth Care
IndustryBiotechnology
Employees670
Market cap$6.5B

Fundamentals

Enterprise value$8.4B
Revenue$562.1M
Revenue per employee
Profit margin-27.70%
Debt to equity208.50

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.52
Dividend per share
Revenue per share$8.85
Avg trading volume (30 day)$661M
Avg trading volume (10 day)$360M
Put-call ratio

Macro factor sensitivity

Growth+0.4
Credit+6.2
Liquidity+2.1
Inflation-4.4
Commodities-0.6
Interest Rates-0.3

Valuation

Dividend yield0.00%
PEG Ratio-136.54
Price to sales14.77
P/E Ratio-136.54
Enterprise Value to Revenue14.97
Price to book24.22

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend day

News

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

CNBC Television (June 2, 2025)
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.

Zacks Investment Research (June 2, 2025)
Sanofi-Blueprint deal is a bullish signal about biotech M&A

The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. Sanofi is set to buy Blueprint Medicines for over $9 billion, while Bristol-Myers Squibb plans to license a cancer drug from BioNTech.

Yahoo Finance (June 2, 2025)
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.

Benzinga (November 14, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free